# Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is a public company headquartered in San Diego, CA, United States.

## Company overview

- **Legal name:** Calidi Biotherapeutics, Inc.
- **Former names in filing history:** Calidi Biotherapeutics, Inc. (2023-09-25 to 2026-09-25); First Light Acquisition Group, Inc. (2021-05-17 to 2023-09-19)
- **Classification:** Public company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** San Diego, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001855485

## About

Calidi Biotherapeutics develops investigational oncology technologies using engineered oncolytic viruses. Its RedTail platform is designed to deliver genetic medicines to tumor sites, with CLD-401 identified as its first candidate from that platform. These development aims do not establish regulatory approval or demonstrated patient benefit. The company reported an offering closing on September 21, 2026. A separate September equity-compliance notice set an October 21 deadline for submitting a compliance plan. Its reported principal executive office is in San Diego, CA (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included a net loss of USD 19,906,000; cash used in operations of USD 21,293,000. At that year-end, it reported total assets of USD 8,857,000. Historical figures retain the originally filed amounts where later comparative figures differ.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Net income:** -$19.9M (USD -19,906,000)
- **Total assets:** $8.9M (USD 8,857,000)
- **Operating cash flow:** -$21.3M (USD -21,293,000)

### FY2024 (period ended 2024-12-31)

- **Net income:** -$22.1M (USD -22,143,000)
- **Total assets:** $14.2M (USD 14,182,000)
- **Cash and equivalents:** $9.6M (USD 9,600,000)
- **Operating cash flow:** -$19.7M (USD -19,694,000)

### FY2023 (period ended 2023-12-31)

- **Net income:** -$29.2M (USD -29,216,000)
- **Total assets:** $10.0M (USD 10,019,000)
- **Operating cash flow:** -$27.0M (USD -26,983,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** $3.5M (USD 3,530,190)
- **Total assets:** $42.9M (USD 42,854,778)
- **Operating cash flow:** $98,051 (USD 98,051)
- **Later filings:** Net income, Total assets, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2026-09-25 — period 2026-09-21 — 8-K
- Form 8-K — filed 2026-09-22 — period 2026-09-17 — 8-K
- Form 10-Q — filed 2026-08-13 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-13 — period 2026-08-13 — 8-K
- Form 8-K — filed 2026-07-31 — period 2026-07-27 — 8-K
- Form 8-K — filed 2026-07-16 — period 2026-07-10 — 8-K
- Form 8-K — filed 2026-06-23 — period 2026-06-17 — 8-K
- Form 8-K — filed 2026-06-18 — period 2026-06-12 — 8-K
- Form 8-K — filed 2026-05-29 — period 2026-05-28 — 8-K
- Form 10-Q — filed 2026-05-14 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-14 — period 2026-05-14 — 8-K
- Form 8-K — filed 2026-05-08 — period 2026-05-06 — 8-K

---

Updated: 2026-10-15T21:34:01.423Z

Canonical page: https://altss.com/profile/calidi-biotherapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology